Patents by Inventor Anders Nykjær

Anders Nykjær has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294569
    Abstract: The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 5, 2024
    Inventors: Paul Brian LITTLE, Manuel Javier CASES-THOMAS, Mads Fuglsang KJØLBY, Anders NYKJÆR
  • Publication number: 20240217922
    Abstract: The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.
    Type: Application
    Filed: April 22, 2022
    Publication date: July 4, 2024
    Inventors: Paul Brian LITTLE, Manuel Javier CASES-THOMAS, Mads Fuglsang KJØLBY, Anders NYKJÆR
  • Publication number: 20240132514
    Abstract: The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.
    Type: Application
    Filed: January 20, 2022
    Publication date: April 25, 2024
    Inventors: Paul Brian LITTLE, Manuel Javier CASES-THOMAS, Mads Fuglsang KJØLBY, Anders NYKJÆR
  • Publication number: 20230374143
    Abstract: The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I), (II), (III), and (IV), in the treatment or prevention of hearing loss. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of hearing loss in a subject in need thereof.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 23, 2023
    Inventors: Mads Fuglsang KJØLBY, Anders NYKJÆR, Paul LITTLE, Manuel CASES
  • Publication number: 20230144901
    Abstract: The present invention relates to the use of sortilin antagonists, in particular compounds of Formula (I) and preferably Formula (II), in the treatment or prevention of diabetic retinopathy. Also provided are pharmaceutical compositions comprising the sortilin antagonists herein disclosed and methods for the treatment or prevention of diabetic retinopathy in a subject in need thereof.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 11, 2023
    Inventors: Mads Fuglsang KJOLBY, Anders NYKJAER, Paul LITTLE, Andreas JURGEIT
  • Publication number: 20230044608
    Abstract: The present invention concerns an anti-sortilin antibody or an antigen binding fragment thereof, for use in the treatment or prevention of a disease of the eye, in particular diseases or disorders of the retina, the choroid and/or the optic nerve.
    Type: Application
    Filed: December 10, 2020
    Publication date: February 9, 2023
    Inventors: Anders Nykjær, Anne Louise Askou, Thomas Juhl Corydon, Toke Bek
  • Publication number: 20220033470
    Abstract: The invention provides composition comprising a fragment, derivative or variant of sortilin, or a sortilin mimetic, for use in medicine, wherein the sortilin mimetic is not SorCS1, SorCS2, SorCSS or SorLA. The composition preferably for use in treating or preventing diabetes mellitus, insulin resistance, obesity, metabolic disorders, polycystic ovary syndrome, non-alcoholic fatty liver disease, retinopathy, neuropathy, nephropathy, Alzheimer's disease and/or cardiovascular disease in a subject in need thereof. Also provided are isolated polypeptides, nucleic acids encoding the polypeptides, vectors, host cells and expression systems containing the nucleic acids and methods for making the polypeptides.
    Type: Application
    Filed: December 13, 2019
    Publication date: February 3, 2022
    Inventors: Mads Fuglsang KJØLBY, Anders NYKJÆR, Søren THIRUP
  • Patent number: 10172918
    Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for the treatment of obesity.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: January 8, 2019
    Assignee: Aarhus Universitet
    Inventors: Karen-Marie Pedersen, Anders Nykjaer, Mads Fuglsang Kjolby
  • Patent number: 9931374
    Abstract: The present invention relates to Sor CS1-like agents, including Sor CS1, nucleic acid molecule encoding expression of Sor CS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing Sor CS1 and said fragments, for use in the treatment of insulin resistance.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: April 3, 2018
    Assignee: Aarhus Universitet
    Inventors: Karen-Marie Pedersen, Anders Nykjaer
  • Publication number: 20170318057
    Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.
    Type: Application
    Filed: July 11, 2017
    Publication date: November 2, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Anders Nykjær, Mads Fuglsang Kjølby
  • Publication number: 20170240611
    Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 24, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Simon Glerup Pedersen, Ulrich Bolcho, Kimmo Jensen, Anders Nykjaer
  • Publication number: 20170158766
    Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Anders Nykjaer, Claus Munck Petersen
  • Patent number: 9670263
    Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 6, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Simon Glerup Pedersen, Ulrich Bolcho, Kimmo Jensen, Anders Nykjaer
  • Patent number: 9605073
    Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: March 28, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Anders Nykjaer, Claus Munck Petersen
  • Publication number: 20170014476
    Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for the treatment of obesity.
    Type: Application
    Filed: June 9, 2016
    Publication date: January 19, 2017
    Inventors: Karen-Marie Pedersen, Anders Nykjaer, Mads Fuglsang Kjolby
  • Publication number: 20160349276
    Abstract: The present invention relates to the use of Sortilin as a biomarker. In particular, Sortilin is useful as a biomarker for affective disorders. In one aspect of the invention Sortilin may be used to aid the diagnosing and to monitor disease progression in bipolar disorder and unipolar depression by measuring Sortilin levels. The invention further provides methods for informing the choice of treatment of bipolar disorder and unipolar depression by determining the levels of Sortilin.
    Type: Application
    Filed: February 6, 2015
    Publication date: December 1, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Jesper Lundhede Jepsen, Anders Nykjær, Niels Peter Ole Mors, Claus Munck Petersen, Søren Dinesen Østergaard, Simon Glerup
  • Patent number: 9387232
    Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for the treatment of obesity.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: July 12, 2016
    Assignee: Aarhus Universitet
    Inventors: Karen-Marie Pedersen, Anders Nykjaer, Mads Fuglsang Kjolby
  • Publication number: 20160060346
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 3, 2016
    Applicant: H. LUNDBECK A/S
    Inventors: Olav Michael Andersen, Anders Nykjær
  • Publication number: 20160015778
    Abstract: The present invention relates to Sor CS1-like agents, including Sor CS1, nucleic acid molecule encoding expression of Sor CS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing Sor CS1 and said fragments, for use in the treatment of insulin resistance.
    Type: Application
    Filed: June 29, 2015
    Publication date: January 21, 2016
    Inventors: Karen-Marie Pedersen, Anders Nykjaer
  • Patent number: 9234036
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: January 12, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Olav Michael Anderson, Anders Nykjaer